Universitat Autònoma de Barcelona (UAB) Jun 5 2026 In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi TM , from Biogen) and donanemab (Kisunla TM , from Eli Lilly and Company), both based on immunotherapy (the use of molecules from the immune system to treat diseases). These antibodies, obtained in the laboratory, act against the Aβ peptide, a protein fragment that accumulates in the brain of patients with Alzheimer's disease. The fact